Arjun Gupta1, Avash Das2, Kaustav Majumder3, Nivedita Arora1, Helen G Mayo4, Preet P Singh5, Muhammad S Beg6, Siddharth Singh7. 1. Department of Internal Medicine. 2. Division of Cardiology, Massachusetts General Hospital, Boston, MA. 3. Department of Surgical Sciences, University of Minnesota, Minneapolis, MN. 4. University of Texas Southwestern Medical Center Library, Dallas, TX. 5. Division of Hematology/Oncology, Springfield Clinic, Springfield, IL. 6. Division of Hematology Oncology, University of Texas Southwestern Medical Center. 7. Division of Gastroenterology, University of California San Diego, La Jolla, CA.
Abstract
OBJECTIVE: Excess body weight is associated with increased risk of developing hepatocellular cancer (HCC), but its effect on HCC-related mortality remains unclear. We performed a systematic review and meta-analysis to assess the association between premorbid obesity and HCC-related mortality. MATERIALS AND METHODS: Through a systematic literature search-up to March 2016, we identified 9 observational studies (1,599,453 individuals, 5705 HCC-related deaths) reporting the association between premorbid body mass index (BMI), and HCC-related mortality. We estimated summary adjusted hazard ratio (aHR) with 95% confidence intervals (CIs), comparing obese (BMI>30 kg/m(2)) and overweight (BMI, 25 to 29.9 kg/m(2)) individuals with normal BMI individuals using random-effects model. RESULTS: On meta-analysis, compared with individuals with normal BMI, obese (aHR, 1.95; 95% CI, 1.46-2.46), but not overweight individuals (aHR, 1.08; 95% CI, 0.97-1.21), had higher HCC-related mortality, with moderate heterogeneity. On subgroup analysis, magnitude of increased mortality was higher in obese men (aHR, 2.50; 95% CI, 2.02-3.09; 3 studies) as compared with obese women (aHR, 1.45; 95% CI, 1.08-1.97; 2 studies). The impact of premorbid obesity on HCC-related mortality was observed only in western populations (aHR, 2.10; 95% CI, 1.77-2.48; 4 studies), but not Asian populations (aHR, 1.10; 95% CI, 0.63-1.92; 1 study). There was limited assessment of competing risk because of advanced liver disease. CONCLUSIONS: On the basis of this meta-analysis, premorbid obesity may be independently associated with a 2-fold risk of HCC-related mortality. This association was more pronounced in men and western populations. Strategies targeting obesity-associated metabolic abnormalities may provide novel pathways for HCC therapy.
OBJECTIVE: Excess body weight is associated with increased risk of developing hepatocellular cancer (HCC), but its effect on HCC-related mortality remains unclear. We performed a systematic review and meta-analysis to assess the association between premorbid obesity and HCC-related mortality. MATERIALS AND METHODS: Through a systematic literature search-up to March 2016, we identified 9 observational studies (1,599,453 individuals, 5705 HCC-related deaths) reporting the association between premorbid body mass index (BMI), and HCC-related mortality. We estimated summary adjusted hazard ratio (aHR) with 95% confidence intervals (CIs), comparing obese (BMI>30 kg/m(2)) and overweight (BMI, 25 to 29.9 kg/m(2)) individuals with normal BMI individuals using random-effects model. RESULTS: On meta-analysis, compared with individuals with normal BMI, obese (aHR, 1.95; 95% CI, 1.46-2.46), but not overweight individuals (aHR, 1.08; 95% CI, 0.97-1.21), had higher HCC-related mortality, with moderate heterogeneity. On subgroup analysis, magnitude of increased mortality was higher in obesemen (aHR, 2.50; 95% CI, 2.02-3.09; 3 studies) as compared with obesewomen (aHR, 1.45; 95% CI, 1.08-1.97; 2 studies). The impact of premorbid obesity on HCC-related mortality was observed only in western populations (aHR, 2.10; 95% CI, 1.77-2.48; 4 studies), but not Asian populations (aHR, 1.10; 95% CI, 0.63-1.92; 1 study). There was limited assessment of competing risk because of advanced liver disease. CONCLUSIONS: On the basis of this meta-analysis, premorbid obesity may be independently associated with a 2-fold risk of HCC-related mortality. This association was more pronounced in men and western populations. Strategies targeting obesity-associated metabolic abnormalities may provide novel pathways for HCC therapy.
Authors: O Simmons; D T Fetzer; T Yokoo; J A Marrero; A Yopp; Y Kono; N D Parikh; T Browning; A G Singal Journal: Aliment Pharmacol Ther Date: 2016-11-08 Impact factor: 8.171
Authors: Allison A Hedley; Cynthia L Ogden; Clifford L Johnson; Margaret D Carroll; Lester R Curtin; Katherine M Flegal Journal: JAMA Date: 2004-06-16 Impact factor: 56.272
Authors: Carl J Lavie; Alban De Schutter; Parham Parto; Eiman Jahangir; Peter Kokkinos; Francisco B Ortega; Ross Arena; Richard V Milani Journal: Prog Cardiovasc Dis Date: 2016-01-28 Impact factor: 8.194
Authors: Turan Aghayev; Aleksandra M Mazitova; Jennifer R Fang; Sergei I Grivennikov; Ekaterina K Koltsova; Iuliia O Peshkova; Matthew Rausch; Manhsin Hung; Kerry F White; Ricard Masia; Elizaveta K Titerina; Aliia R Fatkhullina; Isabelle Cousineau; Simon Turcotte; Dmitry Zhigarev; Anastasiia Marchenko; Svetlana Khoziainova; Petr Makhov; Yin Fei Tan; Andrew V Kossenkov; David L Wiest; John Stagg; Xin Wei Wang; Kerry S Campbell; Amiran K Dzutsev; Giorgio Trinchieri; Jonathan A Hill Journal: Cancer Discov Date: 2022-08-05 Impact factor: 38.272
Authors: Fasiha Kanwal; Saira Khaderi; Amit G Singal; Jorge A Marrero; Nicole Loo; Sumeet K Asrani; Christopher I Amos; Aaron P Thrift; Xiangjun Gu; Michelle Luster; Abeer Al-Sarraj; Jing Ning; Hashem B El-Serag Journal: Hepatology Date: 2022-03-01 Impact factor: 17.298